Cargando…
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
INTRODUCTION: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). METHODS: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, multicenter, dose-finding, phase 2b study. Adults with...
Autores principales: | Dicpinigaitis, Peter V., Morice, Alyn H., Smith, Jaclyn A., Sher, Mandel R., Vaezi, Michael, Guilleminault, Laurent, Niimi, Akio, Gude, Kerstin, Krahn, Ulrike, Saarinen, Riitta, Pires, Philippe Vieira, Wosnitza, Melanie, McGarvey, Lorcan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234230/ https://www.ncbi.nlm.nih.gov/pubmed/37261531 http://dx.doi.org/10.1007/s00408-023-00621-x |
Ejemplares similares
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2022) -
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021) -
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022) -
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023) -
Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature
por: Holmes, Joshua, et al.
Publicado: (2022)